venBio Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/venBio Partners/Activity

venBio Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Novo Nordisk completed its acquisition of portfolio company Akero Therapeutics.

Akero Therapeutics

Akero Therapeutics venBio Partners

biospace.comDEC 9, 2025

DEC 9, 2025

News

Portfolio company Candid Therapeutics was recognized as a 2025 Endpoints 11 Honoree.

Candid Therapeutics named a 2025 Endpoints 11 Honoree

venBio Partners

venbio.comSEP 19, 2025

SEP 19, 2025

Exit

Portfolio company Vicebio was acquired by Sanofi for approximately $1.6 billion.

Vicebio

Vicebio venBio Partners

venbio.comJUL 22, 2025

JUL 22, 2025

Milestone

Pharvaris updated the timing of topline data for its RAPIDe-3 pivotal Phase 3 study to Q4 2025.

Pharvaris

Pharvaris venBio Partners

venbio.comJUL 10, 2025

JUL 10, 2025

Exit

Portfolio company Verona Pharma entered a definitive agreement to be acquired by Merck for approximately $10 billion.

Verona Pharma

Verona Pharma venBio Partners

merck.comJUL 9, 2025

JUL 9, 2025

4 milestones· MAY 2025 – JUN 2025Show all

Milestone

Candid Therapeutics advanced its portfolio of novel T-cell engagers into five autoimmune disease indications for clinical evaluation.

Candid Therapeutics

Candid Therapeutics venBio Partners

venbio.comJUN 20, 2025

JUN 20, 2025

Milestone

Harmony Biosciences strengthened its patent position with a favorable settlement in ANDA litigation.

Harmony Biosciences

Harmony Biosciences venBio Partners

venbio.comJUN 5, 2025

JUN 5, 2025

Milestone

Pharvaris presented data supporting ongoing clinical development of deucrictibant in bradykinin-mediated angioedema.

Pharvaris

Pharvaris venBio Partners

venbio.comJUN 2, 2025

JUN 2, 2025

Milestone

Marea Therapeutics published positive Phase 2a clinical trial data for MAR001 in The Lancet.

Marea Therapeutics

Marea Therapeutics venBio Partners

venbio.comMAY 16, 2025

MAY 16, 2025

Investment

Co-led (with Cormorant Asset Management) Axonis Therapeutics' oversubscribed $115M Series A to advance a first-in-class KCC2 potentiator for epilepsy and pain.

Axonis Therapeutics

Axonis Therapeutics venBio Partners

prnewswire.comOCT 30, 2024

OCT 30, 2024

3 new funds· APR 2020 – AUG 2024Show all

New Fund

Raised a $528 million venture capital fund focused on life science companies.

Fund V ($528M)

venBio Partners

businesswire.comAUG 2024

AUG 2024

New Fund

Raised a $550 million venture capital fund focused on life sciences.

Fund IV ($550M)

venBio Partners

businesswire.comJUN 2021

JUN 2021

New Fund

Closed a $394 million life sciences venture capital fund.

Fund III ($394M)

venBio Partners

businesswire.comAPR 2020

APR 2020